跳轉至內容
Merck
  • [Clinical experience of autologous blood transfusion in patients undergoing nephrectomy with renal cell carcinoma].

[Clinical experience of autologous blood transfusion in patients undergoing nephrectomy with renal cell carcinoma].

Hinyokika kiyo. Acta urologica Japonica (1992-02-01)
K Nomura, M Hasegawa, K Ishikura, J Mathuzaka, Y Suzuki, K H Yeh, T Okamoto, S Tanji, K Suzuki, T Fujioka
摘要

We studied the possibility of performing radical nephrectomy with only predeposit autologous blood transfusion in the treatment of patients with renal cell carcinoma. A total of 15 patients who ranged in age from 32 to 69 years and had a hemoglobin concentration of over 12 g/dl on admission underwent radical nephrectomy with preoperative autologous blood donation. Five patients did not need transfusions. Seven patients were transfused only autologous blood. The other 3 required some homologous blood in addition to their own banked blood. In our series, patients were able to donate 600 ml of blood during the last week before surgery and their hemoglobin concentration did not decrease by over 2 g/dl except in the case of two patients with advanced disease. Therefore, it was concluded that an adequate autologous blood volume for nephrectomy was 600 ml and that 80% of renal cell carcinoma surgery could be performed without homologous blood transfusion. For patients requiring resection of renal cell carcinoma, autologous transfusion is recommended as safe and convenient.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
胡黄连苷I, ≥98% (HPLC)